Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

This Phase II study is testing a combination of furmonertinib (a targeted lung cancer drug) and bevacizumab (an anti-blood vessel drug) as first-line treatment for people with EGFR-mutated non-small cell lung cancer that has spread to the brain. **You may be eligible if...** - You are 18 to 75 years old in reasonably good health (ECOG 0-2) - You have confirmed non-squamous NSCLC with a specific EGFR mutation (19del or L858R) - You have brain metastases that are either asymptomatic or have controlled symptoms - You have at least one brain lesion of at least 5mm visible on MRI - You have not received prior systemic treatment for advanced or metastatic NSCLC - Your blood counts, kidney, liver, and heart function meet required levels **You may NOT be eligible if...** - You have active bleeding in the brain or leptomeningeal disease with active bleeding - You previously received bevacizumab or similar anti-VEGF drugs - You have had prior whole-brain radiation - You have poorly controlled high blood pressure, heart problems, or serious bleeding history - You have active hepatitis, HIV, or active tuberculosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.